Clinical

The OVERLORD-MS trial finds rituximab matches ocrelizumab in relapsing multiple sclerosis, with similar MRI control, relapses, and safety.

All from July, these 5 novel therapeutics each claimed a “first” in their category.

In this episode, 'Comparing the Two Approved Therapies: Dextromethorphan-Bupropion and Brexpiprazole in Alzheimer's Disease Agitation,' the expert neurologists explored the following question: What were the key safety and efficacy results that led to its approval and how do they compare with brexpiprazole's?

In 'Brexpiprazole and Dextromethorphan-Buproprion: Mechanisms of Action and Key Clinical Trial Data for Approved Alzheimer's Disease Agitation Therapies,' the expert neurologists examined the following critical questions: Brexpiprazole was approved by the Food and Drug Administration (FDA) in 2023 and dextromethorphan/buproprion in 2026 for the treatment of Alzheimer's disease agitation. What are the mechanisms of action of these therapies? What were the key safety and efficacy results seen in the clinical trials?

Phase 3 SOLARIS found high-dose vitamin D3 added to standard chemotherapy did not significantly improve progression-free survival in metastatic CRC.

Katherine Wilemon, Family Heart Foundation, described the biggest unmet need when it comes to public awareness of Lp(a) and its associated risk factors.

MASLD was linked to higher odds of EoE and reflux-related diseases, suggesting metabolic dysfunction may contribute to esophageal disease.

Tara Graff described her approach to communicating PFS data with patients, explaining that rather than using clinical terminology, she frames progression-free survival in terms patients can connect with, presenting treatment options side by side and translating trial outcomes into plain language estimates of how long a given therapy is likely to keep their disease in remission.

Dr. Buchfuhrer examined the persistence of TNF cycling in clinical practice despite observational data, including a large-scale study of more than 15,000 patients, showing that most patients who fail one TNF inhibitor are kept on the same drug class rather than switched.

Tara Graff noted that while RRFL patients themselves do not look fundamentally different between community and academic settings, what varies is how those patients are managed at relapse, with disease trajectory serving as one of the most critical and sometimes underappreciated factors in community practice treatment decision-making.

Dr. Buchfuhrer discussed defining remission, rather than low disease activity, as the treatment target for RA, describing it as the point where a patient no longer needs to consciously check in with their joints day to day.

Steven D. Nathan, MD, discusses inhaled treprostinil and why inhaled therapies could mark the next frontier in idiopathic pulmonary fibrosis (IPF) care.

Matched real-world MCL data shows acalabrutinib and zanubrutinib lower atrial fibrillation vs ibrutinib, with fewer bleeding events.

ORIGIN trial data suggest atacicept (Trutakna; Vera Therapeutics) is well tolerated in IgA nephropathy, with follow-up needed to assess long-term kidney outcomes.

Researchers found no evidence that cooling beyond 6 hours at 33°C improved neurological outcomes in comatose survivors of out-of-hospital cardiac arrest.

The accreditation body targets sourcing, testing, and marketing practices, as the FDA advisory panel recommends expanding access to compounded peptides.

How tebentafusp, a BiTE bispecific T-cell engager, changes metastatic uveal melanoma care—HLA testing, dosing, safety and access tips for clinics.

Peter Forsberg, MD, discusses why health systems must adapt to expand equitable access to CAR T-cell and bispecific therapies.

The FDA approval of atacicept introduces the first BAFF/APRIL dual inhibitor for IgA nephropathy, with trial data showing significant proteinuria reduction.

John Kitchens, MD, explores how GLP-1s, novel drug pipelines, and Medicaid access gaps are shaping the future of DME management.

Brittany G. Craiglow, MD, FAAD, discusses the psychiatric and psychosocial toll of alopecia in children and adolescents, and its impact on treatment initiation.

FAQs address Cyclospora recovery, high-risk populations, antibiotic use, C. difficile risk, and CDC/FDA outbreak response.

The Pharmacy Compounding Advisory Committee narrowly recommended BPC-157, KPV, TB-500, MOTS-c, Semax, and epitalon for the 503A Bulks List.

People with HIV born after 1980 had an 81% lower risk of hepatitis B coinfection than earlier cohorts, highlighting the lasting impact of childhood vaccination.

New data suggest acalabrutinib appears to reduce the target that macrophages are supposed to recognize in patients with CLL.